In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma

Abstract

In the present study, we have developed an efficient targeted non-viral vector for IL-12 gene transfer in hepatocellular carcinoma in vivo, by employing non-toxic cationic PLGA/DOTAP/AF nanoparticles. These results demonstrate for the first time that this cationic system could be used successfully and safely for delivery of therapeutic genes with antitumor activity into liver tumors with targeting specificity.

Nano-drugs therapy for hepatocellular carcinoma

“…For the transport of interleukin 12 (IL-12) into the tumour, Diez et al (2009) created lipopolymeric cationic micelles which combined the polymer and dioleoyloxytrimethylammonium propane (DOTAP) lipids. These complexes carrying the gene IL-12 were administered to murine subjects with a murine undifferentiated subcutaneous HCC.…”

“…These complexes carrying the gene IL-12 were administered to murine subjects with a murine undifferentiated subcutaneous HCC. Survival was up to 60 days compared to administration of IL-12 without a carrier, with complete tumour regression of 75 % in the group with IL-12 transported in nano-complexes [12].…”

Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance

“…It was found that the receptor dissociation constant of such compounds is 200-fold lower than that of glycoproteins with biantennary N-linked oligosaccharide chains. Hence, it has been used as a competitive inhibitor of various other polysaccharides which show high affinity to the receptors (Díez et al, 2009). Cationic nanoparticles were prepared using asialofetuin as targeting ligand and found that targeted-nanoparticles showed about 5-to 12-fold higher transfection activity as compared to non-targeted (plain) complexes in the liver.…”

Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail

“…Active targeting of tumor cells by conjugate targeting moieties to NPs lead to accumulation of NPs in tumor sites. The antibodies bind to an antigen on the tumor cell surface and assist NPs drug delivery system to tumor sites [94][95][96][97]. Lyp-1 nanoparticles target specific peptide of (PEG -PLGA) NPs to tumor lymph metastasis is a promising carrier to target specific drug delivery to lymphatic metastasis tumor [98].…”